ELI LILLY AND COMPANY |
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
| 848 EUR | +0,43 % |
|
-0,19 % | +60,23 % |
| 08/07 | El S&P 500 y el Nasdaq amplían sus rachas récord al cierre | MT |
| 08/07 | El S&P 500 y el Nasdaq amplían sus máximos históricos al cierre | MT |
Resumen de negocios
- endocrinología (57,7%): productos para el tratamiento de la osteoporosis, la diabetes y los problemas de crecimiento;
- oncología (19,5%);
- enfermedades inmunológicas (11,1%);
- neurología (8,4%): principalmente medicamentos utilizados en el tratamiento de la depresión y la esquizofrenia;
- otros (3,3%).
Las ventas netas se distribuyen geográficamente del siguiente modo: Estados Unidos (63,9%), Europa (18,1%), Japón (4,9%), China (4,5%) y otros (8,6%).
Ventas por actividad
| USD en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56 % |
Ventas por región
| USD en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80 % |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62 % |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30 % |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28 % |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98 % |
Directores
| Directores | Puesto | Edad | Desde |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/10/23 |
Alonzo Weems
CMP | Compliance Officer | - | 01/01/97 |
| Chief Tech/Sci/R&D Officer | 50 | 01/01/18 | |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17/05/21 |
Johna Norton
PRN | Corporate Officer/Principal | 57 | 01/04/17 |
| Corporate Officer/Principal | - | 01/01/05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
| - | - |
Administradores
| Administradores | Puesto | Edad | Desde |
|---|---|---|---|
| Director/Board Member | 63 | 25/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/04/09 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 01/01/05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01/02/16 |
William Kaelin
BRD | Director/Board Member | 66 | 04/06/12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01/10/16 |
| Director/Board Member | 52 | 12/12/11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01/09/13 |
Karen Walker
BRD | Director/Board Member | 62 | 01/12/18 |
Clase de acciones
| Vote | Quantity | Flotante | Autocontrol | Total Float | |
|---|---|---|---|---|---|
| Acción A | 1 | 950 770 386 | 948 828 530 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Participaciones
| Nombre | Acciones | % | Valoración |
|---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2 548 145 | 6.25% | 86 356 634 $ |
| 8 084 411 | 6.83% | 40 989 257 $ | |
| 4 000 000 | 7.23% | 23 000 000 $ | |
PROQR THERAPEUTICS N.V. 16.37% | 13 371 562 | 16.37% | 22 196 793 $ |
AC IMMUNE SA 3.64% | 3 615 328 | 3.64% | 14 425 159 $ |
| 21 776 804 | 7.60% | 10 654 955 $ | |
| 2 500 000 | 7.07% | 8 811 050 $ | |
| 125 405 | 1.81% | 1 220 191 $ |
Información de la empresa
Empresas del grupo
| Nombre | Categoría y sector |
|---|---|
ELI Lilly & Company (India) Pvt Ltd.
 ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
 Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Eli Lilly Export SA (Switzerland)
 Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Kinsale Financial Services
| |
Lilly Nederland Finance BV
 Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands. |
Miscellaneous Commercial Services
|
Eli Lilly SA
 Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Eli Lilly (Suisse) SA
| |
Lilly Global Nederland Holdings BV
 Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands. |
Financial Conglomerates
|
Eli Lilly Vostok SA
|
Ventas por región
Revisiones del BPA
| Varia. 1 de ene. | Capi. | |
|---|---|---|
| -7,18 % | 353 mil M | |
| +15,37 % | 320 mil M | |
| +7,45 % | 295 mil M | |
| +13,62 % | 239 mil M | |
| +14,55 % | 220 mil M | |
| -0,33 % | 219 mil M | |
| +8,14 % | 167 mil M | |
| -2,99 % | 159 mil M | |
| +2,61 % | 123 mil M |
- Bolsa de valores
- Acciones
- Acción LLY
- Acción LLY
- Empresa Eli Lilly and Company
